BIOLASE Company Profile (NASDAQ:BIOL)

About BIOLASE (NASDAQ:BIOL)

BIOLASE logoBIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BIOL
  • CUSIP: N/A
  • Web: www.biolase.com
Capitalization:
  • Market Cap: $79.16 million
  • Outstanding Shares: 67,660,000
Average Prices:
  • 50 Day Moving Avg: $1.26
  • 200 Day Moving Avg: $1.46
  • 52 Week Range: $0.80 - $1.98
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.70
  • P/E Growth: -0.43
Sales & Book Value:
  • Annual Revenue: $51.67 million
  • Price / Sales: 1.53
  • Book Value: $0.27 per share
  • Price / Book: 4.33
Profitability:
  • EBIDTA: ($13,600,000.00)
  • Net Margins: -25.50%
  • Return on Equity: -53.73%
  • Return on Assets: -30.49%
Debt:
  • Current Ratio: 2.27%
  • Quick Ratio: 1.44%
Misc:
  • Average Volume: 65,044 shs.
  • Beta: 1.89
  • Short Ratio: 32.73
 

Frequently Asked Questions for BIOLASE (NASDAQ:BIOL)

What is BIOLASE's stock symbol?

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

How were BIOLASE's earnings last quarter?

BIOLASE Inc (NASDAQ:BIOL) posted its quarterly earnings results on Wednesday, May, 3rd. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.03. The company earned $10.87 million during the quarter. BIOLASE had a negative return on equity of 53.73% and a negative net margin of 25.50%. View BIOLASE's Earnings History.

Where is BIOLASE's stock going? Where will BIOLASE's stock price be in 2017?

1 brokers have issued twelve-month target prices for BIOLASE's shares. Their predictions range from $2.50 to $2.50. On average, they expect BIOLASE's share price to reach $2.50 in the next year. View Analyst Ratings for BIOLASE.

Are investors shorting BIOLASE?

BIOLASE saw a decline in short interest during the month of April. As of April 28th, there was short interest totalling 2,505,302 shares, a decline of 1.4% from the April 13th total of 2,541,687 shares. Based on an average daily volume of 63,377 shares, the short-interest ratio is currently 39.5 days.

Who are some of BIOLASE's key competitors?

Who owns BIOLASE stock?

BIOLASE's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Oracle Investment Management Inc. (21.64%), Vanguard Group Inc. (2.35%), Birchview Capital LP (1.90%), Granite Investment Partners LLC (1.48%), Teton Advisors Inc. (0.51%) and Trellus Management Company LLC (0.43%). Company insiders that own BIOLASE stock include David C Dreyer, Jack W Schuler, Larry N Feinberg and Paul N Clark. View Institutional Ownership Trends for BIOLASE.

Who sold BIOLASE stock? Who is selling BIOLASE stock?

BIOLASE's stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. View Insider Buying and Selling for BIOLASE.

Who bought BIOLASE stock? Who is buying BIOLASE stock?

BIOLASE's stock was purchased by a variety of institutional investors in the last quarter, including Trellus Management Company LLC, Granite Investment Partners LLC, Geode Capital Management LLC and Vanguard Group Inc.. Company insiders that have bought BIOLASE stock in the last two years include David C Dreyer, Jack W Schuler, Larry N Feinberg and Paul N Clark. View Insider Buying and Selling for BIOLASE.

How do I buy BIOLASE stock?

Shares of BIOLASE can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of BIOLASE stock cost?

One share of BIOLASE stock can currently be purchased for approximately $1.17.

Analyst Ratings

Consensus Ratings for BIOLASE (NASDAQ:BIOL) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.50 (113.68% upside)

Analysts' Ratings History for BIOLASE (NASDAQ:BIOL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/25/2017Singular ResearchInitiated CoverageBuy$2.50LowView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for BIOLASE (NASDAQ:BIOL)
Earnings by Quarter for BIOLASE (NASDAQ:BIOL)
Earnings History by Quarter for BIOLASE (NASDAQ:BIOL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017Q1 2017($0.03)($0.06)$10.87 millionViewListenView Earnings Details
3/8/2017Q4 2016$0.02($0.06)$13.76 millionViewListenView Earnings Details
11/8/2016Q316($0.02)($0.05)$12.40 million$13.20 millionViewListenView Earnings Details
5/9/2016Q116($0.03)($0.07)$11.90 million$11.00 millionViewN/AView Earnings Details
3/9/2016Q415($0.09)($0.04)$13.90 million$14.50 millionViewN/AView Earnings Details
11/4/2015Q315($0.08)($0.09)$1.50 million$11.20 millionViewN/AView Earnings Details
11/4/2014Q314($0.09)($0.08)$11.70 million$12.70 millionViewN/AView Earnings Details
8/7/2014Q214($0.08)($0.17)$12.97 million$10.20 millionViewN/AView Earnings Details
5/12/2014Q114($0.05)($0.11)$13.29 million$11.50 millionViewN/AView Earnings Details
3/5/2014Q413($0.04)($0.04)$15.67 million$15.20 millionViewN/AView Earnings Details
11/5/2013Q313($0.05)($0.10)$16.42 million$12.30 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.04)($0.06)$15.69 million$14.20 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.01)($0.06)$14.48 million$14.60 millionViewN/AView Earnings Details
3/6/2013Q4 2012$0.05$18.03 million$19.10 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BIOLASE (NASDAQ:BIOL)
Current Year EPS Consensus Estimate: $-0.14 EPS
Next Year EPS Consensus Estimate: $-0.10 EPS

Dividends

Dividend History for BIOLASE (NASDAQ:BIOL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for BIOLASE (NASDAQ:BIOL)
Insider Ownership Percentage: 7.30%
Institutional Ownership Percentage: 34.15%
Insider Trades by Quarter for BIOLASE (NASDAQ:BIOL)
Institutional Ownership by Quarter for BIOLASE (NASDAQ:BIOL)
Insider Trades by Quarter for BIOLASE (NASDAQ:BIOL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/18/2016Jack W SchulerMajor ShareholderBuy500$0.80$400.00View SEC Filing  
2/17/2016Jack W SchulerMajor ShareholderBuy4,100$0.80$3,280.00View SEC Filing  
2/12/2016Jack W SchulerMajor ShareholderBuy19,080$0.76$14,500.80View SEC Filing  
2/10/2016Jack W SchulerMajor ShareholderBuy67,213$0.78$52,426.14View SEC Filing  
1/25/2016Jack W SchulerMajor ShareholderBuy1,400$0.80$1,120.00View SEC Filing  
1/22/2016Jack W SchulerMajor ShareholderBuy6,670$0.78$5,202.60View SEC Filing  
1/20/2016Jack W SchulerMajor ShareholderBuy24,200$0.75$18,150.00View SEC Filing  
12/28/2015Jack W SchulerMajor ShareholderBuy18,350$0.79$14,496.50View SEC Filing  
12/24/2015Jack W SchulerMajor ShareholderBuy41,900$0.76$31,844.00View SEC Filing  
12/22/2015Jack W SchulerMajor ShareholderBuy87,200$0.74$64,528.00View SEC Filing  
12/21/2015Jack W SchulerMajor ShareholderBuy127,892$0.73$93,361.16View SEC Filing  
12/17/2015Jack W SchulerMajor ShareholderBuy34,158$0.70$23,910.60View SEC Filing  
11/11/2015Larry N FeinbergMajor ShareholderBuy54,800$0.79$43,292.00View SEC Filing  
11/10/2015Paul N ClarkDirectorBuy134,579$0.75$100,934.25View SEC Filing  
9/24/2015David C DreyerCFOBuy5,000$1.20$6,000.00View SEC Filing  
9/22/2015David C DreyerCFOBuy5,000$1.37$6,850.00View SEC Filing  
9/17/2015David C DreyerCFOBuy10,000$1.45$14,500.00View SEC Filing  
11/3/2014Jeffrey M NugentCEOBuy40,465$2.39$96,711.35View SEC Filing  
11/3/2014Jonathan T Md LordDirectorBuy101,163$2.39$241,779.57View SEC Filing  
11/3/2014Larry N FeinbergMajor ShareholderBuy2,067,979$2.39$4,942,469.81View SEC Filing  
7/22/2014Alexander K ArrowCOOBuy7,812$1.92$14,999.04View SEC Filing  
7/22/2014Frederick D FurryCFOBuy13,020$1.92$24,998.40View SEC Filing  
7/22/2014Jeffrey M NugentCEOBuy52,083$1.92$99,999.36View SEC Filing  
7/22/2014Paul N ClarkDirectorBuy520,833$1.92$999,999.36View SEC Filing  
7/18/2014Larry N FeinbergMajor ShareholderBuy2,270,836$1.92$4,360,005.12View SEC Filing  
2/12/2014Larry N FeinbergMajor ShareholderBuy2,035,033$2.57$5,230,034.81View SEC Filing  
1/31/2014Larry Feinbergmajor shareholderBuy30,798$2.45$75,455.10View SEC Filing  
12/19/2013Larry Feinbergmajor shareholderBuy340,000$1.80$612,000.00View SEC Filing  
12/17/2013Larry Feinbergmajor shareholderBuy150,400$1.87$281,248.00View SEC Filing  
8/23/2012Frederick D FurryCFOBuy5,075$1.64$8,323.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for BIOLASE (NASDAQ:BIOL)
Latest Headlines for BIOLASE (NASDAQ:BIOL)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to BIOLASE, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 3:52 PM
americanbankingnews.com logoShort Interest in BIOLASE Inc (BIOL) Drops By 1.4%
www.americanbankingnews.com - May 13 at 7:08 PM
finance.yahoo.com logoETFs with exposure to BIOLASE, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 4:28 PM
finance.yahoo.com logoBIOLASE, Inc. :BIOL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
finance.yahoo.com - May 9 at 3:56 PM
finance.yahoo.com logoBIOLASE Announces Management Change
finance.yahoo.com - May 5 at 3:56 PM
americanbankingnews.com logoBIOLASE Inc (BIOL) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS
www.americanbankingnews.com - May 4 at 9:00 PM
finance.yahoo.com logoEdited Transcript of BIOL earnings conference call or presentation 3-May-17 8:30pm GMT
finance.yahoo.com - May 4 at 4:03 PM
finance.yahoo.com logoBIOLASE Reports 2017 First Quarter Results
finance.yahoo.com - May 3 at 6:14 PM
marketbeat.com logoBiolase reports 1Q loss
marketbeat.com - May 3 at 6:05 PM
americanbankingnews.com logoSomewhat Favorable Media Coverage Somewhat Likely to Impact BIOLASE (BIOL) Share Price
www.americanbankingnews.com - May 2 at 11:26 PM
americanbankingnews.com logoBIOLASE Inc (BIOL) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 1 at 1:18 PM
americanbankingnews.com logoBIOLASE (BIOL) Earning Somewhat Favorable News Coverage, Report Finds
www.americanbankingnews.com - April 26 at 2:32 PM
finance.yahoo.com logoBIOLASE® to Host 2017 First Quarter Financial Results Conference Call on May 3
finance.yahoo.com - April 26 at 12:27 PM
americanbankingnews.com logoBIOLASE Inc (BIOL) Coverage Initiated at Singular Research
www.americanbankingnews.com - April 25 at 3:06 PM
streetinsider.com logoForm 4 BIOLASE, INC For: Apr 18 Filed by: LORD JONATHAN T MD
www.streetinsider.com - April 19 at 9:14 PM
americanbankingnews.com logoBIOLASE (BIOL) Earning Somewhat Favorable Media Coverage, Report Finds
www.americanbankingnews.com - April 17 at 5:25 PM
americanbankingnews.com logoBIOLASE (BIOL) Earning Positive News Coverage, Report Shows
www.americanbankingnews.com - April 14 at 5:40 PM
finance.yahoo.com logoBIOLASE to Raise $10.5 Million from Institutional and Individual Investors in a Private Placement
finance.yahoo.com - April 13 at 4:03 PM
bizjournals.com logoREGISTER TODAY: Multidisciplinary Treatment Solutions for Peri-Implantitis Symposium
www.bizjournals.com - April 7 at 3:52 PM
uk.finance.yahoo.com logoBIOLASE to Showcase Two New Game-Changing Products at International Dental Show in Cologne
uk.finance.yahoo.com - March 20 at 11:08 AM
finance.yahoo.com logoBIOLASE, INC Financials
finance.yahoo.com - March 16 at 3:22 PM
finance.yahoo.com logoBIOLASE Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - March 14 at 8:41 AM
finance.yahoo.com logoBIOLASE Names James D. Surek Vice President Sales, Americas
finance.yahoo.com - March 13 at 11:12 AM
biz.yahoo.com logoBIOLASE, INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 10 at 4:44 PM
finance.yahoo.com logoBIOLASE to Present at the 29th Annual ROTH Conference
finance.yahoo.com - March 9 at 4:27 PM
reuters.com logoBRIEF-Biolase Q4 loss per share $0.07
www.reuters.com - March 9 at 2:42 AM
biz.yahoo.com logoQ4 2016 BIOLASE Inc Earnings Release - After Market Close
biz.yahoo.com - March 8 at 4:40 PM
biz.yahoo.com logoQ4 2016 BIOLASE Inc Earnings Release - After Market Close
biz.yahoo.com - March 8 at 4:40 PM
finance.yahoo.com logoBIOLASE Reports 2016 Full Year and Fourth Quarter Results
finance.yahoo.com - March 8 at 4:40 PM
finance.yahoo.com logoBIOLASE Reports 2016 Full Year and Fourth Quarter Results
finance.yahoo.com - March 8 at 4:40 PM
biz.yahoo.com logoBIOLASE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - March 8 at 4:40 PM
biz.yahoo.com logoBIOLASE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - March 8 at 4:40 PM
biz.yahoo.com logoBIOLASE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Officer
biz.yahoo.com - March 1 at 8:55 PM
finance.yahoo.com logoBIOLASE® to Host 2016 Fourth Quarter Financial Results Conference Call on March 8
finance.yahoo.com - March 1 at 8:39 AM
biz.yahoo.com logoBIOLASE, INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - February 22 at 4:00 PM
finance.yahoo.com logoBIOLASE to Host ‘Lasers for Every Dentist’ Launch Celebration at Chicago Midwinter Dental Meeting
finance.yahoo.com - February 21 at 10:41 AM
finance.yahoo.com logoBIOLASE Announces the FDA Clearance and Worldwide Launch of New Waterlase Express™ All-Tissue Laser System
finance.yahoo.com - February 10 at 3:24 PM
finance.yahoo.com logo6:01 am Biolase receives 510(k) clearance for its fifth-generation Waterlas Express for commercial distribution from the FDA in the U.S. as well as select international markets in Europe, the Middle East and Asia
finance.yahoo.com - February 10 at 3:24 PM
businesswire.com logoBIOLASE Announces the FDA Clearance and Worldwide Launch of Its New Epic Pro™ Diode Laser System - Business Wire (press release)
www.businesswire.com - January 25 at 4:24 PM

Social

Chart

BIOLASE (BIOL) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff